Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
Driving advances in cancer care
Dedicated investigators and clinicians bring expertise in drug development and flexible study design
Tumor-infiltrating lymphocytes and natural killer cells
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy